Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Liver Cirrhosis

Free Subscription Articles published in Lancet Retrieve available abstracts of 14 articles: HTML format

Single Articles

April 2026
1. GRAUPERA I, Thiele M, Castera L, Pera G, et al
   Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.
   Lancet. 2026;407:1448-1458.
   PubMed     Abstract available
   
   
   March 2026
2. VON SETH E, Karlsen TH, Tanaka A, Ponsioen C, et al
   Primary sclerosing cholangitis.
   Lancet. 2026 Mar 20:S0140-6736(25)02582-6. doi: 10.1016/S0140-6736(25)02582.
   PubMed     Abstract available
   
   
   February 2026
3. VALENTI L, Periti G
   Once-monthly efimosfermin for non-cirrhotic MASH.
   Lancet. 2026 Feb 5:S0140-6736(25)02431-6. doi: 10.1016/S0140-6736(25)02431.
   PubMed    
   
   
   
4. NOUREDDIN M, Kowdley KV, Odrljin T, Bain G, et al
   Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.
   Lancet. 2026 Feb 5:S0140-6736(25)02276-7. doi: 10.1016/S0140-6736(25)02276.
   PubMed     Abstract available
   
   
   November 2025
5. NOUREDDIN M, Harrison SA, Loomba R, Alkhouri N, et al
   Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
   Lancet. 2025 Nov 11:S0140-6736(25)02114-2. doi: 10.1016/S0140-6736(25)02114.
   PubMed     Abstract available
   
   
   August 2025
6. LOOMBA R, Morgan E, Yousefi K, Li D, et al
   Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
   Lancet. 2025;406:821-831.
   PubMed     Abstract available
   
   
   
7. NOUREDDIN M, Frias JP, Neff GW, Lucas KJ, et al
   Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
   Lancet. 2025;406:719-730.
   PubMed     Abstract available
   
   
   May 2025
8. COOKE GS, Hung LM, Flower B, McCabe L, et al
   Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
   Lancet. 2025 May 7:S0140-6736(25)00097-2. doi: 10.1016/S0140-6736(25)00097.
   PubMed     Abstract available
   
   
   November 2024
9. ISRAELSEN M, Francque S, Tsochatzis EA, Krag A, et al
   Steatotic liver disease.
   Lancet. 2024;404:1761-1778.
   PubMed     Abstract available
   
   
   September 2024
10. TANAKA A, Ma X, Takahashi A, Vierling JM, et al
    Primary biliary cholangitis.
    Lancet. 2024;404:1053-1066.
    PubMed     Abstract available
    
    
    September 2023
11. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    PubMed    
    
    
    
12. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    PubMed     Abstract available
    
    
    May 2023
13. ADAMS PC, Jeffrey G, Ryan J
    Haemochromatosis.
    Lancet. 2023;401:1811-1821.
    PubMed     Abstract available
    
    
    February 2023
14. JENG WJ, Papatheodoridis GV, Lok ASF
    Hepatitis B.
    Lancet. 2023 Feb 9:S0140-6736(22)01468-4. doi: 10.1016/S0140-6736(22)01468.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum